Browsing Tag
Eric Lefkofsky
3 posts
Tempus AI company profile: How diagnostics, health data and AI are building a precision medicine platform
Tempus AI, Inc. has built a precision medicine business around genomic diagnostics, multimodal health data, artificial intelligence and pharmaceutical research services. Ambry Genetics, Deep 6 AI, Paige and OneOme have widened that platform, while the proposed Personalis acquisition could bring molecular residual disease technology, laboratory economics and longitudinal cancer monitoring more tightly inside the company.
Tempus AI agrees to acquire Personalis in $1.5bn precision oncology deal built around a $46 floor price
Tempus AI to buy Personalis at $16.25 per share in a $1.5B stock-plus-optional-cash deal, with a $46 Tempus floor that gives Personalis the right to walk if breached.
Tempus AI shakes up precision medicine with $600m acquisition of Ambry Genetics
Tempus AI has taken a significant step in advancing its precision medicine strategy by agreeing to acquire Ambry…